Zacks Investment Research disclosed GenVec Inc (NASDAQ:GNVC), upping its target price to $0.50 today
- Updated: October 5, 2016
In a report announced on 10/5/2016 Zacks Investment Research bumped up the price target of GenVec Inc (NASDAQ:GNVC) to $0.50 stating a potential upside of 0.19%.
Just yesterday GenVec Inc (NASDAQ:GNVC) traded -3.94% lower at $0.42. GenVec Inc’s 50-day moving average is $0.55 and its 200-day moving average is $0.64. The last stock close price is down -35.98% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 99,538 shares of the stock were exchanged, down from an average trading volume of 142,657
See Chart Below
GenVec Inc has a 52 week low of $0.35 and a 52 week high of $3.69 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 1 broker has issued a report on the stock. The consensus target price is $5.00 with 0 brokers rating the stock a strong buy, 0 equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.
Brief Synopsis About GenVec Inc (NASDAQ:GNVC)
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.